Singapore Markets open in 5 hrs 42 mins

ANI Pharmaceuticals, Inc. (ANIP)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
47.300+0.16 (+0.34%)
As of 3:15PM EDT. Market open.
People also watch
AMAGENTAAGIOANIKALDR
Full screen
Previous close47.140
Open47.140
Bid47.540 x 100
Ask47.660 x 100
Day's range46.830 - 47.990
52-week range42.560 - 70.920
Volume124,526
Avg. volume132,801
Market cap550.38M
Beta2.72
PE ratio (TTM)147.81
EPS (TTM)0.32
Earnings date4 May 2017 - 8 May 2017
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est62.50
Trade prices are not sourced from all markets
  • ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : June 27, 2017
    Capital Cubeyesterday

    ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : June 27, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ANI Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • PR Newswire8 days ago

    ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets

    BAUDETTE, Minn., June 20, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5mg/0.025mg.  The annual U.S. market for Diphenoxylate HCl and Atropine Sulfate Tablets is approximately $56 million, per IMS Health.  Prior to ANI's launch there were two companies marketing a generic version of this drug product. Arthur S. Przybyl, ANI's President and CEO stated, "This is the seventh product that ANI has successfully re-commercialized from its portfolio of acquired discontinued ANDA products.  Through the end of the first quarter of 2017, ANI had re-commercialized five of the 54 acquired products.

  • Capital Cube9 days ago

    ETFs with exposure to ANI Pharmaceuticals, Inc. : June 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ANI Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ANIP-US. Comparing the performance and risk of ANI Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)